Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Varsha Gandhi, PhD, on Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Feb
26
Today In Oncology
Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC
FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer
MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo